Table 1.

SMARTrial participant characteristics

Characteristics	Total (N = 80)
Sex
Male	48 (60%)
Female	32 (40%)
Age (years)
Median [minimum, maximum]	68.5 [20.0, 91.0]
Diagnosis
AML	34 (42%)
ALL	2 (2%)
DLBCL	4 (5%)
BL	1 (1%)
FL	3 (4%)
MCL	5 (6%)
CLL	25 (31%)
B-PLL	1 (1%)
T-PLL	4 (5%)
T cell lymphoma, NOS	1 (1%)
Time from initial diagnosis (months)
≤12	49 (61%)
>12	31 (39%)
Prior lines of treatment
≥3	6 (8%)
0	54 (68%)
1	11 (14%)
2	9 (11%)
Tumor sample origin
Peripheral blood	59 (74%)
Bone marrow	12 (15%)
Lymph node	9 (11%)
Tumor infiltration of sample
Median [minimum, maximum]	84.5 [52.0, 99.0]
Prescribed treatment at study entry
Chemotherapy	28 (35%)
Chemotherapy + small-molecule inhibitors	7 (9%)
Immunochemotherapy	16 (20%)
Immunotherapy	2 (2%)
Small-molecule inhibitors	27 (34%)

Data are number of participants (%) or median [range]. Percentages may not total 100 because of rounding.

NOS, not otherwise specified.